Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 244

1.

Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Jr JJE, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, Sengupta D, Das M.

AIDS. 2019 Mar 29. doi: 10.1097/QAD.0000000000002223. [Epub ahead of print]

PMID:
30932951
2.

REPLY TO Lanzafame, Lattuada and Vento.

Martin EA, Hwang C, Orkin C.

Clin Infect Dis. 2019 Mar 20. pii: ciz229. doi: 10.1093/cid/ciz229. [Epub ahead of print] No abstract available.

PMID:
30891586
3.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
4.

Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services.

Finnerty F, Azad Y, Orkin C.

Lancet HIV. 2019 Feb;6(2):e76. doi: 10.1016/S2352-3018(19)30004-9. No abstract available.

PMID:
30723011
5.

Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.

Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT; UK HIV Drug Resistance Database and UK CHIC Study .

J Antimicrob Chemother. 2019 Mar 1;74(3):746-753. doi: 10.1093/jac/dky468.

6.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
7.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.

Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.

8.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M.

HIV Med. 2018 Nov;19(10):724-733. doi: 10.1111/hiv.12664. Epub 2018 Aug 12.

9.

Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health.

Psomas C, Kinloch S, Sabin C, Soriano V, Solas C, Orkin C, Bernardino J, Curran A, Routy JP, Enel P, Philibert P, Lafeuillade A.

J Virus Erad. 2018 Jul 1;4(3):196-207.

10.

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV.

Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA, Post FA; UK CHIC Study .

J Infect Dis. 2018 Oct 20;218(11):1767-1772. doi: 10.1093/infdis/jiy397.

11.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
12.

A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study.

Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K, Sabin CA; UK CHIC Study Steering Committee.

Lancet HIV. 2018 Jun;5(6):e301-e308. doi: 10.1016/S2352-3018(18)30048-1.

13.

A systematic review of risk of HIV transmission through biting or spitting: implications for policy.

Cresswell FV, Ellis J, Hartley J, Sabin CA, Orkin C, Churchill DR.

HIV Med. 2018 Apr 23. doi: 10.1111/hiv.12625. [Epub ahead of print]

14.

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.

Eron JJ, Orkin C, Gallant J, Molina JM, Negredo E, Antinori A, Mills A, Reynes J, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Vanveggel S, Opsomer M; AMBER study group.

AIDS. 2018 Jul 17;32(11):1431-1442. doi: 10.1097/QAD.0000000000001817.

15.

Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department - uncovering the iceberg?

Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C.

Epidemiol Infect. 2018 Jun;146(8):1026-1035. doi: 10.1017/S0950268818000870. Epub 2018 Apr 17.

PMID:
29661260
16.

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P; UK HIV Drug Resistance Database; UK Collaborative HIV Cohort.

AIDS Res Ther. 2018 Apr 16;15(1):11. doi: 10.1186/s12981-018-0198-7.

17.

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.

Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV.

J Viral Hepat. 2018 Oct;25(10):1180-1188. doi: 10.1111/jvh.12917. Epub 2018 May 8.

PMID:
29660224
18.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.

Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M.

Clin Infect Dis. 2018 Sep 14;67(7):1010-1017. doi: 10.1093/cid/ciy220.

19.

Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.

Cevik M, Orkin C.

Curr Opin HIV AIDS. 2018 Jul;13(4):315-319. doi: 10.1097/COH.0000000000000465. Review.

PMID:
29528852
20.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

Supplemental Content

Loading ...
Support Center